Osiris Therapeutics competitorsClear all

Osiris Therapeutics's top competitors include GenSight Biologics, Immusoft, Reneuron Group and Eloxx Pharmaceuticals.

Save Comparison	Osiris Therapeutics Osiris Therapeutics researches, develops, manufactures, markets, and distributes regenerative medicine products in the United States.	GenSight Biologics GenSight Biologics develops gene therapy-based treatments for retinal degenerative diseases.	Immusoft Immusoft is a biotechnology company commercializing technologies that program the human immune system by modifying the DNA in related cells.	Reneuron Group ReNeuron Group engages in R&D and the commercial exploitation of stem cell technologies for therapeutic and non-therapeutic applications.	Eloxx Pharmaceuticals Eloxx Pharmaceuticals is a clinical-stage biopharmaceutical company developing treatments for rare and ultra-rare genetic diseases.
Founding Date	Founding Date 1992	Founding Date 2011	Founding Date 2009	Founding Date 1997	Founding Date 2013
Type	Type Public	Type Public	Type Private	Type Public	Type Public
Tags	Tags Healthcare biotech genetics	Tags Healthcare biotech genetics	Tags Healthcare biotech genetics	Tags Healthcare biotech genetics	Tags Healthcare biotech genetics
Locations	Locations Columbia, US HQ	Locations Paris, FR HQ New York, US	Locations Seattle, US HQ	Locations Surrey Research Park, GB HQ	Locations Waltham, US HQ Rehovot, IL
Employees	Employees 3421% increase	Employees 37	Employees 19	Employees 5320% increase	Employees 2993% increase
Valuation ($)	Valuation ($) 655.7 m	Valuation ($) 118.4 m	Valuation ($) N/A	Valuation ($) 73.5 m	Valuation ($) 351.2 m
Alexa Website Rank	Alexa Website Rank 527479	Alexa Website Rank 804029	Alexa Website Rank N/A	Alexa Website Rank 1071527	Alexa Website Rank N/A
Financial
Revenue (est.)	Revenue (est.) $142.8m (FY, 2018)	Revenue (est.) N/A	Revenue (est.) N/A	Revenue (est.) £43k (FY, 2018)	Revenue (est.) N/A
Net income	Net income $36.9m (FY, 2018)	Net income N/A	Net income N/A	Net income (£17.6m) (FY, 2018)	Net income ($47.2m) (FY, 2018)
Funding
Total funding raised	Total funding raised $ 65m	Total funding raised $ 103.1m	Total funding raised $ 9.4m	Total funding raised $ 38.4m	Total funding raised $ 30m